Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Core Insights - Aclarion, Inc. announced the addition of Keck Medical Center of USC as a site for the CLARITY trial, aimed at demonstrating the clinical and economic value of Nociscan in spine surgery [1][2] - The CLARITY trial will evaluate 300 patients undergoing surgical treatment for discogenic low back pain, with a primary endpoint of measuring changes in back pain at 12 months [3][4] Company Overview - Aclarion is a healthcare technology company utilizing biomarkers and AI algorithms to assist physicians in identifying chronic low back pain [1][6] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][6] Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving multiple high-volume sites across the US, including notable institutions like Johns Hopkins Medicine and Northwestern Medicine [2][3] - The trial will randomize patients in a 1:1 ratio between surgeons who are blinded and unblinded to Nociscan results [3] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting a significant healthcare challenge [4] - Aclarion's Nociscan aims to improve surgical outcomes by providing insights into the sources of low back pain through advanced diagnostic techniques [4][7]